Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
In the last few years, more information has been published regarding birth defects associated with the use of the new generation of antiepileptic drugs (AEDs). Some recent reports from different registries have shown a lower rate of major birth defects associated with the use of new generation AEDs compared with some of the first-generation AEDs. For example, an Australian registry showed no increase in major birth defects with the use of lamotrigine in the first trimester.1 But a North American registry reported a significant increase in the presence of oral clefts in infants exposed to lamotrigine during pregnancy, in contrast with a European registry which showed no association between rate of birth defects and the use of lamotrigine.2 3 Another study from Finland reported no increase in the rate of congenital malformations with the use of oxcarbazepine.4
Molgaard-Nielsen et al published a new study exploring the rate of birth defects associated with the use of some of the new AEDs. This study was based on the Danish medical birth registry. The study included 837 795 live born infants from January 1, 1996 through September 30, 2008. The patient information included in the registry …
Competing interests None.